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ABSTRACT
USD Honors Thesis:
Dementia: types, what they are and how they differ
Jessica Schnetzer
Director: Ranelle Nissen, PhD, OTR/L

Dementia: types, what they are and how they differ centers on the known and unknown
complexities of dementia. Dementia is a very complex cognitive disease that consumes
the brain, an organ of which we know very little about. Even so, this common disorder is
actively being researched and is the topic of special interest of this thesis research.
Described are Alzheimer’s disease, Creutzfeldt-Jakob disease, Frontotemporal dementia,
Huntington’s disease, Korsakoff’s syndrome, Lewy body dementia, Parkinson’s
dementia, and Vascular dementia, focusing on what they are, their specific risks,
diagnosis, treatment, and their differing progressions. Guidance of this study provided by
thesis director Ranelle Nissen, who studies dementia and is a professor at USD. The
remaining two thesis committee members are Mary H. Schmitz, Director of the memory
unit and former director of activities at Grand Living at Lake Lorraine in Sioux Falls, and
Joy Backes, Director of health and wellness, also, at Grand Living at Lake Lorraine; all
of whom have extensive dementia experience and are reliable resources and mentors
during this dementia thesis process.

KEYWORDS: dementia, cognitive disease, disorder, Ranelle Nissen, Mary H. Schmitz,
Joy Backes, Alzheimer’s disease, Creutzfeldt-Jakob disease, Frontotemporal dementia,
Huntington’s disease, Korsakoff’s syndrome, Lewy body dementia, Parkinson’s
dementia, Vascular dementia
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CHAPTER ONE
ALZHEIMER’S DISEASE

What it is and how it differs
Since 1910, the term ‘Alzheimer’s disease’ has been used to describe this illness,
named after Alois Alzheimer (Yang et al., 2016). However, there has been a record of
dementia research specific to this disease before the name was assigned. A Swiss
researcher named Otto Ludwig Binswanger (1852-1929) did research on neurosyphilis, a
causing factor of dementia, along with Dr. Alois Alzheimer (Yang et al., 2016). He
described numerous occurrences of vascular dementia in 1894 and in his report, the term
‘presenile dementia’ was first mentioned (Yang et al., 2016). Later, in 1910, a German
doctor by the name of Emil Kraepelin (1856-1926) developed two classifications of
dementia, splitting its descriptions into senile dementia and presenile dementia (Yang et
al., 2016). He was then the first to title the disease as ‘Alzheimer’s disease’ after Alois
Alzheimer, who discovered pathological features of presenile dementia while working as
the namesake’s student (Yang et al., 2016).
Alzheimer’s disease is the most common form of dementia. Alzheimer’s disease
has two defining factors that separate it from the rest, which are amyloid plaques and
neurofibrillary tangles (Ballard et al., 2011). The key component of neurofibrillary
tangles is a microtubule-associated protein termed tau (Ballard et al., 2011). The amyloid
cascade hypothesis suggests that modifications in tau and resulting neurofibrillary tangle
formations are caused by toxic concentrations of Aβ. Several hypotheses have been
offered on why this occurs; however, the pathways connecting Aß and tau are not plainly
understood (Ballard et al., 2011).
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Specific Risks
Of the 24 million people with dementia, most have been diagnosed with
Alzheimer’s disease, the most common form of dementia (Ballard et al., 2011).
Alzheimer’s has such a high occurrence that it even outnumbers stroke, cardiovascular
disease, and cancer events in people over 60 years of age (Ballard et al., 2011).
Alzheimer’s disease has many risk factors, the most common of which are genetics and
environmental factors (Ballard et al., 2011). The gene with the highest risk factor of
Alzheimer’s disease is the APOE gene, which is involved with the transfer of cholesterols
and can increase a person’s risk of diagnosis by 3-10 times (Ballard et al., 2011).
Environmental factors include lifestyle risks (Obesity, smoking, physical activity,
cognitive reserve, alcohol) and some medical conditions (Midlife hypertension, stroke,
diabetes, midlife hypercholesterolemia) (Ballard et al., 2011). However, because many of
the risk factors come from a person’s lifestyle, a diagnosis of Alzheimer’s disease can be
prevented/ prolonged with appropriate lifestyle changes (Ballard et al., 2011).

Diagnosis and Treatment
Up until recent years, the diagnosis of Alzheimer’s disease was only definitively
possible post mortem (Ballard et al., 2011). With increasing knowledge in neuroimaging
technologies and clinical diagnosis, earlier diagnoses have become possible (Ballard et
al., 2011). When considering the clinical aspects of diagnosis, the patient’s symptoms
are assessed, as well as their family history, which plays a great role in diagnosis (Ballard
et al., 2011). A neuropsychological assessment evaluates certain aspects of possible
cognitive impairment, such as whether social, occupational, or other instrumental
2

functions have been affected (Ballard et al., 2011). There are specific criteria that can be
followed in such assessments: NINCDS-ADRDA (National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders
Association), for example, has over 80% specificity for separating an Alzheimer’s case
from a non-dementia case (Ballard et al., 2011). However, this criterion has proven less
effective when differentiating between a possible Alzheimer’s diagnosis and other
dementia possibilities (Ballard et al., 2011). Neuroimaging is very important when this
comes into play, through which doctors can measure the brain volume of specific
structures in the brain (Ballard et al., 2011). The hippocampus, for example, is an
important focus when diagnosing Alzheimer’s disease, and can help monitor the
progression of the disease, as well as concluding an Alzheimer’s diagnosis (Ballard et al.,
2011). A neuroimaging biomarker assessment is very important in diagnosing a patient,
especially when aligned with clinical symptoms (Ballard et al., 2011). There is a wide
range of treatments available to lessen the clinical symptoms of Alzheimer’s disease;
however, there are no available cures or disease-modifying treatments (Ballard et al.,
2011). Researchers are working to develop treatments that could potentially slow the
progression of the disease through the study of the pathogenesis of brain atrophy in
patients (Ballard et al., 2011). Since there are not treatments available to reverse or slow
the progression of Alzheimer’s disease, early diagnosis is key (Ballard et al., 2011).

Progression
Neuronal dysfunction is caused by “amyloid cascade,” which is a hypothesis
proposing that deposition of amyloid β (Aβ) triggers neuronal dysfunction and death in
the brain (Ballard et al., 2011, p. 1019). This leads to the constant progression of
3

Alzheimer’s disease in patients throughout all stages of the disease (Ballard et al., 2011).
Alzheimer’s disease is extremely common in the dementia field and is trademarked by
progressive memory loss. When a patient first develops the disease, he or she will
experience very short-term memory loss, which will continue to expand to longer-term
memory loss as the disease progresses. Though post-mortem measurements of
deterioration of the brain in Alzheimer’s patients can often directly coordinate with the
patient’s degree of memory loss, this is not the case in some patients, which is where
more research is to be conducted on whether or not these are misdiagnosed, or if there are
other aspects of Alzheimer’s disease that have gone unnoticed in previous studies
(Ballard et al., 2011).

CHAPTER TWO
CREUTZFELDT-JAKOB DISEASE

What it is and how it differs
Discovered in the 1920s by German neurologists Creutzfeldt and Jakob,
Creutzfeldt-Jakob disease (CJD) is a rare form of progressive dementia that’s onset is far
different from any other form of dementia discussed in this review (Tyler, 2003). CJD is
associated with a poorly understood transmissible agent and is an uncommon but
habitually fatal degenerative disease of the central nervous system (Centers for Biologics
Evaluation Research, 2002). The mechanism of contraction and manifestation of this
disease is poorly understood. Research suggests that CJD may be acquired by exogenous
exposure to some sort of infectious material, or may perhaps be hereditary, caused by a
genetic mutation of the prion protein gene (Centers for Biologics Evaluation Research,
2002). There are two types of this disease: new variant Creutzfeldt-Jakob disease
4

(nvCJD) and the general CJD (vCJD), which differ in progression and the average age of
onset, as well as neuropathologic features (Centers for Biologics Evaluation Research,
2002). These variations have been set apart from other forms of dementia, too, because of
their association with bovine spongiform encephalopathy (BSE, also known as “mad cow
disease”), which was introduced after the 1980s-1990s epidemic of BSE in the U.K
(Biologics Evaluation Research, 2002).

Specific Risks
Clinical symptoms of Creutzfeldt-Jakob’s disease occur due to either genetic or
sporadic events. Genetic occurrences result from the aggregation of pathologic isoform
(PrPCJD) in a common protein called the prion protein (PrPC) (Tyler, 2003). Sporadic
occurrences result from abnormal proteins found in the cerebrospinal fluid, most
commonly the 14-3-3 protein (Tyler, 2003). Cruetzfeldt-Jakob’s disease is much rarer
than other diseases with similar symptoms, having a prevalence rate of 1 in every one
million (Tyler, 2003). It became popular to the public during the epidemic of BSE, where
a largely disproportionate amount of people developed cases of new variant CreutzfeldtJakob disease, leading researchers to believe that this condition can also be infectious, as
85% of cases recorded have been listed as sporadic (Tyler, 2003). The compact amount
of irregular prion protein present in vCJD lymphoid tissues issued concerns that the
spread of vCJD by blood could be a larger threat than for genetically-issued CJD (Centers
for Biologics Evaluation Research, 2002). Limited experimental or epidemiological
analyses of vCJD transmissibility by blood or plasma have been published, and it is
unclear whether human blood can transmit the vCJD agent (Centers for Biologics
Evaluation Research, 2002). As a result of this concern, there are new limits on who can
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and cannot donate plasma as an extra precaution when dealing with those who could have
been exposed (Centers for Biologics Evaluation Research, 2002).
Diagnosis and Treatment
Like many other forms of dementia, neuropathologic testing is the only way to
confirm a definitive diagnosis of vCJD, as there are many types of florid plaques possible
in diagnosis, which cannot be confirmed clinically (Tyler, 2003). When looking at the
basal ganglia and thalamus during a diagnosis, spongiform change should be evident with
little distribution in the cerebral cortex of the patient (Tyler, 2003). There may also be a
dense accumulation of abnormal prion proteins, which are specifically shown to be
common in the cerebrum and cerebellum in a person with vCJD (Tyler, 2003). A final
diagnosis is confirmed by the identification of spongiform degeneration, neuronal loss,
and astrogliosis of brain tissue (Centers for Biologics Evaluation Research, 2002). Of
course, a patient is not diagnosed in most cases until clinical symptoms become apparent.
These may include cognitive impairment, pain and paresthesias, dysarthria, and changes
in gait (Centers for Biologics Evaluation Research, 2002).
Immunodiagnosis can also be done through antibody analysis, which can
recognize both normal and pathologic isoforms of PrP (Centers for Biologics Evaluation
Research, 2002). This is done by first providing a pretreatment that causes the antibodies
to break down the normal proteins while leaving the pathologic isoforms intact (Centers
for Biologics Evaluation Research, 2002). There are simple tonsil biopsies that can be
done to diagnose nvCJD, and there is research that suggests the possibility of nasal
biopsies being able to diagnose sporadic CJD, as well (Centers for Biologics Evaluation
Research, 2002). There is not much successful research published for the treatment of
CJD disease; however, medications can alleviate symptoms that develop after the
6

infection subsides. Scientists deem it possible to interfere with the conversion of PrPC to
its pathologic state, which could potentially become a therapeutic target for variants of
this disease in the future (Centers for Biologics Evaluation Research, 2002).

Progression
Creutzfeldt-Jakob disease progresses much more rapidly than most other cases of
dementia, often worsening at a daily pace (Centers for Biologics Evaluation Research,
2002). Common symptoms of early CJD include memory loss, visual hallucinations,
varying types of delusions, and intense emotional and mood changes (Centers for
Biologics Evaluation Research, 2002). As the disease progresses, a patient may
experience “jerking” motor symptoms of the face and limbs, and develop a “startle
myoclonus” upon stimulation (Centers for Biologics Evaluation Research, 2002, p. 1).
The new-variant type of this disease varies greatly from sporadic cases, most importantly
differing in age of onset. The average age of onset of the new-variant type is just 26 years
of age, whereas sporadic cases of Creutzfeldt-Jakob disease occur almost four decades
later (Centers for Biologics Evaluation Research, 2002). In nvCJD, symptoms of
dysphoria, irritability, anxiety, apathy, energy loss, insomnia, and social withdrawal are
common in the early to middle stages, and worsen until the mute phase (Centers for
Biologics Evaluation Research, 2002). The mute phase is typically seen in the late
progression of Creutzfeldt-Jakob disease, which lasts until the patient dies (Centers for
Biologics Evaluation Research, 2002).
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CHAPTER THREE
FRONTOTEMPORAL DEMENTIA

What it is and how it differs
Arnold Pick, a Czech neurologist, first discovered Frontotemporal dementia
(FTD) in 1892. His patient was described to have “progressive deterioration of language
associated with left temporal lobe atrophy,” which would later be termed svPPA, also
known as semantic variant primary progressive aphasia (Olney et al., 2017, p. 340).
Decades later, Frontotemporal dementia research resurfaced upon the publishing of
research conducted by Delay, Brion, and Escourolle. This French group of researchers
published a seminal paper highlighting the clinical and neuropathologic differences
between Alzheimer's and Pick’s disease (Olney, 2017). Pick’s disease was defined to
include frontotemporal atrophy (not including that of the posterior lobes) with histology
that showed inflated cells and cortical-subcortical gliosis. Considering clinical aspects of
the disease, symptoms included increased changes in behavior, lack of insight, and lack
of apraxia and agnosia. These histological and clinical findings can be easily compared to
Alzheimer’s dementia, as it includes diffuse cerebral atrophy and displays neurofibrillary
tangles as well as senile plaques, not to mention the overt presense of agnosia and
apraxia. Because of its evident variance, Constantinidis and colleagues divided Pick’s
disease into three different subtypes much later, in 1974 (Olney, 2017). Interestingly,
only one of the three subtypes displayed the “classic” Pick bodies, signifying that Pick
bodies are not necessary in concluding a diagnosis of Pick’s disease (Olney, 2017).
Currently, FTD comprises clinical disorders that include changes in behavior, language,
executive control, and motor symptoms (Olney et al., 2017). The three core
8

Frontotemporal spectrum disorders discussed are behavioral variant FTD (bvFTD),
nonfluent/agrammatic variant primary progressive aphasia (nfvPPA), and semantic
variant PPA (svPPA) (Olney et al., 2017). FTD is a heterogeneous disorder that involves
a range of specific phenotypes in association with neuropathologic substrates of
frontotemporal lobar degeneration (FTLD) including, but not limited to, FTLD-tau,
FTLD-TDP, and FTLD-FET (Olney et al., 2017).

Specific Risks
Every year, an estimated 1.61 to 4.1 per every 100,000 people in the United States
are diagnosed with Frontotemporal dementia leading to the presence of somewhere
between 20,000 to 30,000 people with this disease in the country at one time (Olney et
al., 2017). Further, Frontotemporal dementia is the second most common dementia in
people who are under the age of 65, following Alzheimer’s disease (Olney et al., 2017).
The typical age range for a Frontotemporal dementia diagnosis is between the ages of 45
and 65, with rare outliers outside this age span (Olney et al., 2017). Overall, gender does
not seem to be a risk factor in the likelihood of developing this disease as supported by a
multitude of statistics (Olney et al., 2017). The most common form of Frontotemporal
dementia is bvFTD, which accounts for a staggering 60% of cases, with the remaining
40% accounting for various language variants of Frontotemporal dementia (Olney et al.,
2017). However, this disease is presumably under diagnosed due to its overlapping
symptoms with a high number of other psychiatric disorders (Olney et al., 2017).
Genetics are also a sizeable risk factor of developing this disease, with 40% of
Frontotemporal dementia cases having strong genetic ties (Olney et al., 2017). This
includes those having a family history of symptoms associated with Frontotemporal
dementia while at least 10% of cases have an autosomal dominant inheritance pattern
9

(Olney et al., 2017). In fact, FTD-MND is the most heritable clinical syndrome with
C9ORF72, MAPT, and GRN being the most common genes associated with
Frontotemporal dementia (Olney et al., 2017).

Diagnosis and Treatment
When diagnosing frontotemporal dementia, priorities include assessing a patient’s
medical and clinical histories in order to pinpoint which area of the brain is affected
(Olney et al., 2017). This is to be done as early on as possible, as new clinical symptoms
develop with further atrophic progression of the disease (Olney et al., 2017). Various
neuroimaging can further support a Frontotemporal dementia diagnosis; however, this is
not always done (Olney et al., 2017). A clinical diagnosis for Frontotemporal dementia
includes assessment of possible impaired confrontation naming, impaired single word
comprehension, impaired object knowledge, or any surface dyslexia or dysgraphia (Olney
et al., 2017). There are no approved treatments for FTD, so a prescribed treatment is
often recommended based on the patient’s symptoms and progression (Olney et al.,
2017). Many medications have been tested for this condition,, including Alzheimer’s
medications, acetylcholinesterase inhibitors, and Mamantine, which have all proved to be
uneffective in treating symptoms (Olney et al., 2017). The most effective drug on the
market for FTD has been found to be limited to serotonin uptake inhibitors, such as
Trazadone, which can help to lessen a patient’s symptoms (Olney et al., 2017).
Antipsychotics are pushed for some symptoms of FTD, but should be used with caution,
as they come with side effects that vary from person to person and is highly understudied
for use in the elderly (Olney et al., 2017). As far as nonpharmaceutical therapies go,
exercise has been proven to show improvement for those patients who can safely endure
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it, and speech therapy is typically effective in the early stages of the disease (Olney et al.,
2017).
Progression
The earliest stages in the progression of Frontotemporal dementia are mild and
can vary depending on where deterioration occurs. A patient often experiences changes in
behavior, personality, emotion, and executive function such as disinhibition, new
compulsions, dietary changes, and symptoms like apathy/lack of empathy are common
(Olney et al., 2017). A common first symptom of frontotemporal dementia is difficulty
with word-finding, or not being able to associate a word with an idea (Olney et al., 2017).
Many of these early symptoms are similar to those seen in psychiatric illness, so in the
early stages, a patient is at risk of misdiagnosis (Olney et al., 2017). Symptoms that are
associated with dysfunction are caused by deterioration in the paralimbic areas of the
brain. These can include the medial frontal, orbital frontal, anterior cingulate, and
frontoinsular cortices (Olney et al., 2017). As the disease progresses, symptoms of
disinhibition begin to manifest. These can include socially inappropriate behavior,
impulsive or careless actions and are linked to right orbital frontal cortex degeneration
(Olney et al., 2017). Self-awareness declines later on in Frontotemporal dementia to
where a patient is no longer able to recognize his or her disease state (Olney et al., 2017).
As the disease progresses, deterioration may favor one part of the brain, making the
symptoms unique from patient to patient. Right temporal atrophy is associated with
behavioral changes, while left temporal lobe atrophy is associated with language
deficiencies (Olney et al., 2017). In the first 5-7 years after diagnosis of right
frontotemporal dementia, symptoms of disinhibition increase and food preference may
change, leading to weight gain (Olney et al., 2017). On the other hand, left
11

frontotemporal dementia is much slower to progress, and so a patient may live a dozen
years after onset (Olney et al., 2017). In left frontotemporal dementia, the semantic
knowledge of the patient is where the most dramatic decline is seen, and severe language
impairments (called “primary progressive aphasia”) manifest in the first 2 years of onset
(Olney et al., 2017). Many patients with left frontotemporal dementia become non-verbal
in the latest stages of the disease (Olney et al., 2017).

CHAPTER FOUR
DEMENTIA AND HUNTINGTON’S DISEASE

What it is and how it differs
In 1872, a 22-year-old American doctor named George Huntington wrote a paper
called On Chorea, describing a hereditary disorder that would later be known as
Huntington’s Chorea, after the paper was published in the Medical and Surgical Reporter
of Philadelphia (Phillips et al., 2001). Huntington’s disease (HD) is a progressive
neurodegenerative disease that has been found to be caused by a glutamine repeat
expansion in mutation huntingtin (mHtt) (Ahmed et al., 2015). This mutation causes
profound neurodegeneration, leading to clinical symptoms of dementia with motor
abnormalities, passed down as an autosomal dominant disorder (Ahmed et al., 2015). The
effects of this disease manifest mainly in the striatum, which results in the dysfunction
and death of striatal medium spiny neurons (Ahmed et al., 2015). HD dementia (HDD) is
widely compared to Alzheimer’s disease due to a majority of similar symptoms;
however, they are not identical and can be easily differentiated during a diagnosis. Those
with HDD will likely display symptoms of attention deficit, cognitive slowing, impaired
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planning and problem solving, and visuoperceptual and construction deficits (Peavy et
al., 2010).

Specific Risks
The biggest risk factor of Huntington’s disease (HD) is its dominant genetic
transmission (Myers, 2004). In fact, descendants of HD carriers have a 50% chance of
developing the disease, with the average onset occurring around age 40 (Myers, 2004). It
is inevitable that a child who inherits the gene will eventually develop the disease with
time (Myers, 2004). There is a grey area as to whether some carriers will develop
Huntington’s disease, depending on the carrier’s trinucleotide repeat, as HD is a
trinucleotide repeat disorder (Myers, 2004). There is an overexpression of CAG repeats
in the Huntington’s disease gene, and the total number of this repeat present in a carrier
determines their likelihood of developing symptoms themselves (Myers, 2004). A typical
amount of these repeats in a person without the gene are 26 or less, whereas repeats of 40
or more are associated with clinical disease expression (Myers, 2004). However, some
carriers with 36 to 39 repeats have the possibility of developing the disease, but typically
any amount of repeats seen between 27 and 39 are usually associated with parental
transmission (Myers, 2004). Gender of the carrier plays a role in how the disease is
passed on (Myers, 2004). A disproportionate number of cases with onset before the age
of 21 had inherited the HD gene from affected fathers, as opposed to maternal
transmission, in which case cases develop later in life (Myers, 2004). This is explained by
meiotic instability of the repeat in paternal transmission, which has the propensity toward
larger repeat expansion, as opposed to possible meiotic instability seen in maternal
transmission (Myers, 2004). This larger size of HD repeats seen in paternal transmission
13

is why a much larger proportion of offspring who express the gene manifests much
earlier in life than those of the maternal germline (Myers, 2004).

Diagnosis and Treatment
The diagnosis of HD is initially diagnosed through simple genetic testing, as
Huntington’s disease is an inherited disease (Myers, 2004). However, early diagnosis of
dementia within this disease is extremely important for assessing a patient’s progression
and developing a treatment plan to alleviate symptoms (Peavy et al., 2010). Testing for
HD occurs under three circumstances including a confirmation diagnosis, predictive
testing of a person hereditarily at risk, and prenatal testing (Myers, 2004). Predictive
testing is often used to decide one’s chances of developing certain characteristics of the
disease, such as dementia, but this, of course, is not definitive (Myers, 2004). It is
essential to look out for any sign of cognitive impairment in Huntington’s disease, as an
early diagnosis of HDD provides a marker for disease progression, a better understanding
of any behavioral changes the patient experiences, and the ability to gain access to
psychosocial and financial resources to compensate for functional impairment (Peavy et
al., 2010). Treatments for Huntington’s are only able to compensate for some symptoms
(Myers, 2004). Although Huntington’s disease is highly researched, there are currently no
treatments available for preventing or delaying the onset of this disease (Myers, 2004).

Progression
The progression of Huntington’s disease differs from other forms of dementia
because it is a relatively early onset and it is slow progressing. Memory decline happens
over time but has been shown to develop relatively later than other forms of dementia
(Peavy et al., 2010). Many studies that assess the progression of Huntington’s disease
14

focus on surveying functional impairment such as “deficits in psychomotor speed,
attention and executive functions, and visuospatial abilities, as well as motor skills
coupled with times visual tracking and demographic variables” (Peavy et al., 2010, p.
1163-1164). A person’s functional ability during the progression of Huntington’s disease
varies greatly from person to person, with the most varying symptom being functional
ability, followed closely by measures of attention and initiation (Peavy et al., 2010). In
order to ensure as much independence as possible in a person with Huntington’s disease,
early diagnosis is key, as the disease is slow-progressing and a person with early
Huntington’s disease can live independently for years after a diagnosis (Peavy et al.,
2010). The first sign of dementia in Huntington’s disease is a change in the patient’s
processing speed, which is first affected before a memory deficit onset (Peavy et al.,
2010). After the initial onset of Huntington’s disease, the average survival time of a
patient with Huntington’s disease is between 17 and 20 years (Myers, 2004).

CHAPTER FIVE
KORSAKOFF’S SYNDROME

What it is and how it differs
The name Korsakoff’s syndrome (KS) comes from Sergei Korsakoff, a Russian
neuropsychiatrist who was the first to discuss a comprehensive interpretation of the
syndrome in a succession of documents published between the years of 1887 and 1891
(Arts et al., 2017). In these, Korsakoff interpreted findings that the syndrome was
typically linked to peripheral nerve inflammation, also known as alcoholic polyneuritis,
and recognized that the disease developed from a toxin. And so, Korsakoff termed the
syndrome “polyneuritic psychosis or cerebropathia psychica toxaemica” (Arts et al.,
15

2017, p. 2876). The term was later changed to Korsakoff’s syndrome by the German
psychiatrist Friedrich Jolly (Arts et al., 2017). It was later discovered by the German
neurophsychiatrist Karl Bonhoeffer that KS had a direct relation to another syndrome
called Wernicke encephalopathy (WE), which results from thiamine deficiency in the
same way that KS does. Bonhoeffer observed that all patients who survived the WE stage
advanced to KS as a residual syndrome (Arts et al., 2017). “KS is a largely irreversible
residual syndrome, caused by severe thiamine deficiency and occurring after incomplete
recovery from a Wernicke encephalopathy, predominantly in the context of alcohol abuse
and malnutrition, characterized by an abnormal mental state in which episodic memory is
affected out of all proportion to other cognitive functions in an otherwise alert and
responsive patient, whose psychological makeup may be further distinguished by
executive dysfunction, flattened affect, apathy, lack of illness insight, and possibly by
fantastic confabulations in the early stage” (Arts et al., 2017, p. 2877).

Specific Risks
The main risk factor for developing Karsakoff’s syndrome (KS) is a thymine
deficiency, which is malnourishment that can arise from many different environmental
factors (Arts et al., 2017). Alcoholism is thought to be the main cause of this deficiency
and is the most common factor known to lead to KS (Arts et al., 2017). There is no
evidence, however, for any other reasoning behind alcoholism leading to KS (Arts et al.,
2017). Other factors that can lead to a deficiency in thymine include hyperemesis
gravidarum, starvation, certain gastrointestinal diseases, AIDS, and bariatric surgery
recovery (Arts et al., 2017). Korsakoff’s syndrome is likely always developed after
Wernicke encephalopathy (WE) if the patient lives long enough (Arts et al., 2017). The
16

only uncertainty that comes with this assumption is that WE is easily overlooked, making
a person with KS unaware of the preceding undiagnosed WE (Arts et al., 2017). In a
paper published by Arts et al., the writers explain that “severe alcohol abuse certainly
contributes to the development of WE: the high-calorie content of alcohol suppresses the
feeling of hunger and favors malnutrition, the combustion of alcohol requires extra
thiamine pyrophosphate (a co-enzyme in energy-bound processes), alcoholic
gastroenteritis impairs the absorption of thiamine, alcoholic liver diseases reduces
thiamine storage in this organ, and alcohol may impair the utilization of thiamine” (2017,
p. 2880).

Diagnosis and Treatment
Diagnosis of Korsakoff’s syndrome is different from many other dementias as it is
not hereditary, and it is the result of WE. WE can be clearly diagnosed with
neuroimaging and can help support a later clinical diagnosis of KS disease (Arts et al.,
2017). The diagnosis of Karsakoff’s syndrome verifies a chronic state of the condition,
rather than the acute state of WE. Symptoms that are looked for in a diagnosis of KS
include dietary deficiencies, oculomotor abnormalities, cerebellar dysfunction, altered
memory state and/or mild memory impairment (Arts et al., 2017). Although thymine
replacement therapy has been proven to be effective for WE, KS is treated differently
(Arts et al., 2017). Since KS is a chronic condition, its treatment is more focused on
lessening dementia symptoms, improving skills that remain, and subduing symptoms that
interfere with the patient’s normal activity (Arts et al., 2017). Though there is current
research in medications such as clonidine, fluvoxamine, reboxetine, and rivastigmine for
the treatment of Karsakoff’s syndrome, there has been no treatment proven to be effective
in delaying the disease (Arts et al., 2017). Any treatments given will be focused solely on
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minimizing the patient’s symptoms.

Progression
KS is the progression of WE, which develops most often from thiamine
deficiency. Once a person is diagnosed with WE, it is fairly simple to treat and recover
from with the use of thiamine replacement treatment (Arts et al., 2017). This can happen
in a few days to weeks if diagnosed and treated early on (Arts et al., 2017). However, if a
patient does not get treatment and have a consistent thiamine deficiency, their disease
becomes persistent and incurable (Arts et al., 2017). This is when they are diagnosed with
Korsakoff’s syndrome. Korsakoff’s syndrome cannot be treated and this is the point in
progression where a patient begins to experience an unalterable cognitive decline due to
permanent damage in the cerebellum (Arts et al., 2017). According to Arts et al., the
progression of WE to KS in alcoholics (the most common risk factor group of KS) has
been proposed to be as much as 85% of cases, with most of these patients develop
“clinically obvious memory impairment” (Arts et al., 2017, p. 2881). In the later stages of
KS, it has been recorded that many of the longest living patients end up with residual
syndromes of dementia such as Alzheimer’s disease. Many have also experienced other
non-dementia related forms of brain damage that manifest as a result of long-term alcohol
abuse (Arts et al., 2017).
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CHAPTER SIX
LEWY BODY DEMENTIA

What it is and how it differs
Dr. Friedrich Lewy discovered Lewy body presence in neurons in 1912 while
working as a neuropathologist of Parkinson’s disease in the laboratory of Dr. Alois
Alzheimer; however, it was not until the 1990s that the cause of these formations could
be explained (Sanford, 2018). It was discovered that the misfolding of α-synuclein
protein causes the formation of Lewy bodies in the nervous system and though the role of
α-synuclein is not evident, it is thought to normally function in cell membrane
remodeling at neuron terminals (Sanford, 2018). Dementia with Lewy bodies (DLB) is
the second most common neurodegenerative dementia, after Alzheimer’s disease
(Sanford, 2018). DLB stems from the development of Lewy bodies, which contain
aggregations of misfolded α-synuclein (Sanford, 2018). These are eventually deposited in
areas of the nervous system, causing neuronal cell death and leading to clinically
ostensible symptoms (Sanford, 2018). Lewy body dementia is an “umbrella” term that
encompasses dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia
(PDD), which have several common symptoms (Sanford, 2018, p. 603). Moreover, DLB
and PDD are almost indistinguishable from one another in their final stages (Sanford,
2018). Each disease progression is the consequence of the aggregation of α-synuclein into
Lewy bodies but is clinically differentiated by the location of their Lewy body deposits
(Sanford, 2018).
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Specific Risks
The accumulation of overexpressed protein oligomers of α-synuclein form the
Lewy bodies associated with Lewy body dementia (Sanford, 2018). Lewy bodies tend to
aggregate in two distinct ways in this disease. Some will deposit predominantly in the
cytoplasm of neurons and lead to multiple system atrophy, while others will deposit in
the cytoplasm of both glial cells and neurons (Sanford, 2018). These formations and
accumulations lead to mitochondrial mutilation and disintegration, eventually provoking
the cascade of cell death, also referred to as apoptosis (Sanford, 2018). This disease
progression is estimated to originate in the enteric nervous system and progress into the
central nervous system, particularly through the vagus nerve, and then into the brain stem
and higher cortical regions. The propagation of Lewy bodies in Lewy body dementia is
considered to follow a comparable pattern to the one suggested for Parkinson’s disease
(Sanford, 2018). Researchers have not been able to clarify why α-synuclein has an initial
tendency to disrupt neurons in the vagus nerve, olfactory nerve, and brainstem nuclei;
however, the accumulation of Lewy bodies in these locations lead to the generic
symptoms seen early on in the disease progression. Some examples of these symptoms
include anosmia resulting from olfactory nerve cell death and constipation as a result of
vagus nerve cell death (Sanford, 2018). One of the earliest indicators of onset is rapid eye
movement (REM) sleep behavior disorder (RBD), a symptom that can arise years before
a Lewy body dementia diagnosis is made. This symptom is the result of Lewy body
buildup in the hypothalamus and reticular activation system (Sanford, 2018).
Following Alzheimer’s disease, Lewy body dementia is the second most common
neurodegenerative dementia, affecting 1.4 million Americans. Its biggest risk factor is
age, as most patients with Lewy body dementia are not diagnosed until around ages 7020

85 years (Sanford, 2018). Gender has proven to be a risk factor for the disease as well as
it is estimated that 70% of diagnosed patients are male (Sanford, 2018). Besides age and
gender, other risk factors to take into account are possible genetic mutations, even though
Lewy body dementia is known to occur sporadically. Yet, there are a few mutual genetic
mutations found in diseased patients, which appear in the leucine-rich receptor kinase 2
(α-synuclein) and glucocerebrosidase A genes (Sanford, 2018).

Diagnosis and Treatment
Dementia with Lewy bodies is commonly underdiagnosed and misdiagnosed
(Sanford, 2018). The common clinical diagnosis will assess for any deficits in motor
function, changes in behavior, mood disorders, and cognitive impairment (Sanford,
2018). However, many of these symptoms overlap with those of other dementias
(Sanford, 2018). The overlap continues into neurological diagnosis, as well, as half of
Alzheimer’s diagnoses are found to have some degree of α-synuclein pathology in
addition to the anticipated pathological findings (Sanford, 2018). Clinically, it is thought
that these overlaps worsen symptoms, but this has not been verified, as there is a
discrepancy in the number of actual cases of DLB as clinical diagnoses differ largely
from post mortem diagnoses (Sanford, 2018). An autopsy after death is the only way to
make a definite diagnosis of DLB, and even then, it is hard to determine a primary
diagnosis when overlapping conditions are present (Sanford, 2018).
Treating this disease has proven to be trivial. There are no disease-modifying
treatments for DLB, only treatments that help to lessen a patient’s symptoms (Sanford,
2018). However, because of the multiple symptoms of this disease, oftentimes multiple
medications are needed, which often have negative effects on opposing symptoms
(Sanford, 2018). Because one drug may improve a symptom while worsening another, it
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is recommended that a patient is introduced to only one medication at a time, making
treatment a cumbersome process for the patient (Sanford, 2018). One symptom that is
recommended to be treated non-pharmacologically is the presence of visual
hallucinations, which is common in patients with DLB (Sanford, 2018). Because of
neuroleptic sensitivity of many with DLB, medications are not given for this symptom,
except in severe cases (Sanford, 2018).

Progression
Development of Lewy bodies in various nuclei in the reticular activating system
of the brainstem can be seen in initial progression stages of Lewy body dementia,
manifesting months to even years before the condition is diagnosed (Sanford, 2018). As
the disease progresses, a patient may experience varying symptoms including
visuospatial deficits, neuroleptic sensitivity, changes in mood, autonomic dysfunction,
and recurrent falls (Sanford, 2018). This is when a patient will begin experiencing a lack
of independence as these issues complicate normal activities such as walking and driving
(Sanford, 2018). Increased cognitive impairment develops, and certain symptoms may
get worse with medications, such as Parkinson-like motor deficits (Sanford, 2018). Mood
symptoms occur, as well, with the course of this disease and can manifest in many ways
including depression, apathy, and anxiety, as well as paranoia, which has been known to
occur in those who experience visual hallucinations (Sanford, 2018). Dementia with
Lewy bodies is a constantly progressing neurodegenerative disease for which there is no
treatment that is able to affect progression, so a patient will continually progress with this
disease until death (Sanford, 2018). The decline of DLB is faster than that of
Alzheimer’s, with patients surviving an average of 4.7 years after initial diagnosis
(Sanford, 2018).
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CHAPTER SEVEN
DEMENTIA AND PARKINSON’S DISEASE

What it is and how it differs
Parkinson’s disease was described in multiple patient documents during the
1700s, but it was not until a man by the name of James Parkinson conducted his medical
description of the disease in 1817 that Parkinson’s was officially defined (Goetz, 2011).
Further research on the disease was conducted in the mid-1800s by Jean-Martin Charcot,
who influenced Parkinson’s research by comparing the disease with another: multiple
sclerosis, along with other disorders that are characterized by tremors (Goetz, 2011).
Parkinson’s disease (PD) and dementia (PDD) greatly decrease a patient’s quality of life
and are often labeled as death sentences, as they decrease a person’s ability to remain
independent (Holden et al., 2016). Though this disease has been thoroughly researched
and is increasingly common, the pathogenic pathways of PD remain poorly understood
(Yang et al., 2018). PD is, in fact, the second-most common neurodegenerative disease
(Yang et al., 2018). Although the pathophysiological signatures are evident in numerous
parts of the brain, the characterizing symptoms of PD which include bradykinesia,
rigidity, abnormal posture, and resting tremor, actually stem predominantly from
progressive loss of DA neurons in the substantia nigra pars compacta (SNc) of the brain
(Yang et al., 2018).

Specific Risks
Parkinson’s disease is the number two most common neurodegenerative illness,
following Alzheimer’s disease (Holden et al., 2016). An estimated 5 million people are
living with this disease, a population that is expected to double in the next 20 years
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(Holden et al., 2016). Parkinson’s disease with dementia, or PDD, worsens the clinical
progression of the disease, decreasing patient independence at a rapid rate (Holden et al.,
2016). Early progression is slow, though, as those who do develop PDD on average were
not diagnosed until 11 years after a PD diagnosis (Holden et al., 2016). For those who
live with Parkinson’s disease for 20 years or more, the chances of PDD are estimated to
increase to as much as 75% (Holden et al., 2016). Although genetic transmission is a
huge risk in Parkinson’s disease, the biggest risk of PDD is its age of onset (Hanagasi et
al., 2017). There is a 12-fold increased risk of developing dementia in late-onset of
Parkinson’s disease compared to those who first experienced symptoms early in life
(Hanagasi et al., 2017).

Diagnosis and Treatment
Those who have been diagnosed with Parkinson’s disease are monitored for
dementia symptoms through cognitive impairment testing and a thorough investigation of
family history. It is unknown where Parkinson’s disease dementia originates, making it
difficult to treat (Yang et al., 2018).
Certain changes in cellular processes have been tested to gain insight on the
possible causes of neuronal depletion: dysregulation of vesicular trafficking, oxidative
stress, disruption of the autophagy/lysosome pathway, mitochondrial dysfunction,
endoplasmic reticulum stress, and Ca2+ homeostasis (Yang et al., 2018). PD has motor
therapies that can help with the disease’s symptoms, but PDD is much harder to treat, as
physical therapies are not effective in the dementia population (Holden et al., 2016).
Treatments for PDD have only marginal therapeutic effects; however, there has been one
medication that has been approved to specifically treat Parkinson’s disease with dementia
(Holden et al., 2016). Rivastigmine, a cholinesterase inhibitor, has been approved by the
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FDA for treatment of this condition but is not able to change the progression of the
disease, only alleviate its symptoms (Holden et al., 2016). The N-methyl-D-aspartate
receptor antagonist Memantine is frequently used in PDD patients, as well, and seems to
have similar effects in lessening Parkinson’s disease and dementia symptoms (Holden et
al., 2016).

Progression
The most common misregulated processes in Parkinson’s disease cortical neurons
are axonal transport, cell adhesion, and mRNA splicing, all of which manifest very early
on in PD progression, before dementia symptoms (Henderson-Smith et al., 2016). Causes
of PD/PDD have been associated with differential alternative splicing in the cortex; the
spread of α-synuclein pathology to the cortex is linked specifically with PDD
(Henderson-Smith et al., 2016). This is slow progressing and can lead to Parkinson’s
disease with or without a dementia presence. Age is an important factor in the
progression of this disease as the older a patient’s Parkinson’s disease manifests, the
quicker it may progress and the likelihood of dementia presence increases. Stated by
Henderson-Smith et al., “RNA-seq clearly reveals the underlying differential alternative
splicing in the posterior cingulate cortex during the course of PD and PDD. Alternative
splicing of ATXN2, HSPH1, SRRM1, RELA, LRRFIP1, and TRIM9 suggests
dysregulation of genes within immune and inflammation responses and transcription and
RNA processing” (2016, p. 6). In this paper, Henderson-Smith et al. describe the
overexpression of genes CSF3 and SELE, in both Parkinson’s disease with dementia and
without, occurring prior to pathological changes that occur in the posterior cingulate
cortex, suggesting there likely being an early role of immune induction in the progression
of Parkinson’s disease, as well (Henderson-Smith et al., 2016, p. 6).
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CHAPTER EIGHT
VASCULAR DEMENTIA

What it is and how it differs
Vascular dementia (VD) studies can be traced back as far as the 1600s when
Thomas Willis described the disease in 1672. However, due to the inability to diagnose
such a disease in a living patient, the typical diagnosis for vascular dementia for centuries
was conjured up to be nothing but “brain congestion,” due to the “effects of untreated
hypertension,” along with other diagnoses such as stroke, anxiety, and cognitive decline
(Román, 2003, p. 11). The modern history of vascular dementia was initiated in 1894
when Otto Binswanger and Alois Alzheimer separated vascular dementia from dementia
paralytica caused by neurosyphilis, which leads to major discoveries and studies of
vascular dementia decades later, in the 1960s, when the seminal neuropathological and
clinical analyses of the New Castle school in England introduced the modern era of
vascular dementia (Román, 2003). Vascular cognitive impairment distinguishes the
diverse nature of the influence of vascular pathology to dementia, as well as other
different subtypes (O’Brien & Thomas, 2015). Though well researched, finding the exact
contribution of cerebrovascular pathology to cognitive decline and dementia has proven
to be exceptionally challenging. While it seems evident that cerebrovascular disease
causes pathological damage and alters cognition, the actual cause remains black-boxed
(O’Brien & Thomas, 2015). This is, in part, because the cognitive changes of vascular
dementia are much more inconsistent than that of other disorders such as Alzheimer's
disease, and are exceedingly dependent on the particular neural substrates affected by
vascular pathology. Symptoms of VD that are most commonly seen, though, include
attention deficits, information processing deficits, and executive function deficits, due to
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the interrupting of frontostriatal circuits (O’Brien & Thomas, 2015).

Specific Risks
Vascular events are the second highest cause of dementia; the first is Alzheimer’s
(O’Brien & Thomas, 2015). The risk of developing dementia due to a vascular event
increases greatly with age, and the number of cases has a history to double approximately
every 5.3 years (O’Brien & Thomas, 2015). In their paper of vascular dementia research,
O’Brien and Thomas explain that “vascular pathology has a heterogeneous nature in
which large vessel atherosclerosis and small vessel arteriosclerosis can lead to cortical
and subcortical infarcts, subinfarct ischaemic lesions (microinfarcts in grey matter and
white matter lesions), and large and small cerebral hemorrhages (microbleeds)” (2015, p.
1675). These events can take place in a variety of areas in the brain and still lead to a
vascular dementia diagnosis (O’Brien & Thomas, 2015). Other events leading to vascular
disease include heart disease, atrial fibrillation, high cholesterol, high homocysteine
concentrations, diabetes, and obesity; however, vascular dementia is most often seen in
post-stroke patients (O’Brien & Thomas, 2015). It is estimated that approximately 1530% of stroke patients will develop dementia within 3 months following the event
(O’Brien & Thomas, 2015). The prolonged instance of delayed dementia occurring in
those who have had a stroke is estimated to be about 20-25% (O’Brien & Thomas, 2015).

Diagnosis and Treatment
For the diagnosis of vascular dementia, a standard dementia screening test is not
enough to pinpoint this specific condition (O’Brien & Thomas, 2015). There are specific
screening tests that can more specifically diagnose vascular dementia: for this, the
Montreal cognitive assessment scale and the vascular dementia assessment scale are used
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for a more accurate diagnosis (O’Brien & Thomas, 2015). To come to a definitive
diagnosis of vascular dementia, a CT scan or MRI is needed to correctly compare brain
activity with clinical symptoms (O’Brien & Thomas, 2015). The CT scans are able to
display infarcts and extensive white matter lesions of the brain, and an MRI examination
can precisely show the location and extent of cerebrovascular disease, but a diagnosis can
be completed with a simple CT scan when compared with clinical symptoms (O’Brien &
Thomas, 2015). There is little explanatory research on the mechanisms of vascular
dementia onset and progression, so there are no approved treatments for this specific
condition (O’Brien & Thomas, 2015). Though there have been minor cognitive benefits
seen with cholinesterase inhibitors and memantine, these medications are not encouraged
due to a higher risk than benefit payoff. There are currently clinical trials on possible
vascular dementia treatments including calcium channel blockers and other agents that
target endothelial function or the renin angiotensin system, but nothing has yet seen
approval (O’Brien & Thomas, 2015).

Progression
Studies on the progression of vascular dementia have been most commonly done
in post-stroke patients, where brain images of those with and without dementia do not
display any notable differences (O’Brien & Thomas, 2015). There have, however, been
several studies that have reported: “lacunes, strategic infarcts, substantial burden of white
matter lesions” consistent in many vascular dementia cases, which presented one or
multiple of these (O’Brien & Thomas, 2015, p. 1673). The presence of white matter
lesions are a common indicator of subcortical vascular disease, which presents itself
without dementia in its early stages (O’Brien & Thomas, 2015). It is worth pointing out
that many of these patients who do experience dementia in this disease more likely than
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not, will be experiencing a form of mixed dementia, of which is to say its cause is not
vascular, though it may contribute to progression (O’Brien & Thomas, 2015). Vascular
dementia arises in the top 10% of the most severe cases of those with a deterioration of
vascular origin (O’Brien & Thomas, 2015). As the disease progresses, assessments must
be done carefully as white matter lesions can indicate other non-ischaemic causes, but it
is safe to draw conclusions of vascular origin in the oldest population (diagnosis at 75
years of age or older) since dementia is commonly more severe in older patients. This
late-onset of cerebrovascular disease may not display dementia immediately, but will
likely progress quickly, often showing signs of cognitive and functional impairment
within three years of onset (O’Brien & Thomas, 2015). Though the pathological
progression of vascular dementia is not well defined, the burden of the disease typically
will increase with age, similar to other forms of dementia (O’Brien & Thomas, 2015). It
is in the best interest of the patient and his or her caregivers to get the earliest diagnosis
possible in order to assess and manage the progression of this form of dementia and to
preserve the patient’s independence as much as possible, mimicking care given to those
with an Alzheimer’s diagnosis, as the progression of AD is much more commonly
assessed (O’Brien & Thomas, 2015).
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